ANI PHARMACEUTICALS, INC (ANIP) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 21.33M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 280.15M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.49B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $21.33M | $280.15M | (m) | (m) | $1.49B | (m) |
| 2026-03-31 | (m) | (m) | $19.30M | $286.00M | (m) | (m) | $1.42B | (m) |
| 2025-12-31 | (m) | (m) | $17.27M | $291.84M | (m) | (m) | $1.44B | (m) |
| 2025-09-30 | (m) | (m) | $15.24M | $297.68M | (m) | (m) | $1.41B | (m) |
| 2025-06-30 | (m) | (m) | $13.22M | $301.48M | (m) | (m) | $1.34B | (m) |
| 2025-03-31 | (m) | (m) | $11.19M | $305.29M | (m) | (m) | $1.29B | (m) |
| 2024-12-31 | (m) | (m) | $9.17M | $309.11M | (m) | (m) | $1.28B | (m) |
| 2024-09-30 | (m) | (m) | $7.15M | $312.92M | (m) | (m) | $1.29B | (m) |
| 2024-06-30 | (m) | (m) | $850.00K | $284.39M | (m) | (m) | $920.75M | (m) |
| 2024-03-31 | (m) | (m) | $850.00K | $284.61M | (m) | (m) | $914.52M | (m) |
| 2023-12-31 | (m) | (m) | $850.00K | $284.82M | (m) | (m) | $904.42M | (m) |
| 2023-09-30 | (m) | (m) | $850.00K | $285.03M | (m) | (m) | $889.91M | (m) |
| 2023-06-30 | (m) | (m) | $850.00K | $285.24M | (m) | (m) | $859.34M | (m) |
| 2023-03-31 | (m) | (m) | $850.00K | $285.46M | (m) | (m) | $765.22M | (m) |
| 2022-12-31 | (m) | (m) | $850.00K | $285.67M | (m) | (m) | $760.09M | (m) |
| 2022-09-30 | (m) | (m) | $850.00K | $285.88M | (m) | (m) | $739.11M | (m) |
| 2022-06-30 | (m) | (m) | $850.00K | $286.10M | (m) | (m) | $751.33M | (m) |
| 2022-03-31 | (m) | (m) | $850.00K | $286.31M | (m) | (m) | $744.85M | (m) |
| 2021-12-31 | (m) | (m) | $850.00K | $286.52M | (m) | (m) | $771.60M | (m) |
| 2021-09-30 | (m) | (m) | $15.93M | $186.06M | (m) | (m) | $470.45M | (m) |
| 2021-06-30 | (m) | (m) | $15.18M | $189.53M | (m) | (m) | $480.16M | (m) |
| 2021-03-31 | (m) | (m) | $14.44M | $168.99M | (m) | (m) | $463.84M | (m) |
| 2020-12-31 | (m) | (m) | $13.24M | $172.44M | (m) | (m) | $461.19M | (m) |
| 2020-09-30 | (m) | (m) | $12.79M | $175.16M | (m) | (m) | $462.58M | (m) |
| 2020-06-30 | (m) | (m) | $12.33M | $177.88M | (m) | (m) | $465.39M | (m) |
| 2020-03-31 | (m) | (m) | $11.87M | $188.09M | (m) | (m) | $482.23M | (m) |
| 2019-12-31 | (m) | (m) | $9.94M | $175.81M | (m) | (m) | $456.79M | (m) |
| 2019-09-30 | (m) | (m) | $4.15M | $64.87M | (m) | (m) | $456.77M | (m) |
| 2019-06-30 | (m) | (m) | $4.15M | $65.69M | (m) | (m) | $446.91M | (m) |
| 2019-03-31 | (m) | (m) | $3.24M | $66.50M | (m) | (m) | $434.39M | (m) |
| 2018-12-31 | (m) | (m) | $3.26M | $67.30M | (m) | (m) | $430.60M | (m) |
| 2018-09-30 | (m) | (m) | $5.69M | $65.95M | (m) | (m) | $439.44M | (m) |
| 2018-06-30 | (m) | (m) | $5.22M | $67.26M | (m) | (m) | $424.18M | (m) |
| 2018-03-31 | (m) | (m) | $3.81M | $68.57M | (m) | (m) | $418.02M | (m) |
| 2017-12-31 | (m) | (m) | $3.35M | $69.95M | (m) | (m) | $412.14M | (m) |
| 2016-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $322.86M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |